OncoKB: A Precision Oncology Knowledge Base
-
Published:2017-11
Issue:1
Volume:
Page:1-16
-
ISSN:2473-4284
-
Container-title:JCO Precision Oncology
-
language:en
-
Short-container-title:JCO Precision Oncology
Author:
Chakravarty Debyani1, Gao Jianjiong1, Phillips Sarah1, Kundra Ritika1, Zhang Hongxin1, Wang Jiaojiao1, Rudolph Julia E.1, Yaeger Rona1, Soumerai Tara1, Nissan Moriah H.1, Chang Matthew T.1, Chandarlapaty Sarat1, Traina Tiffany A.1, Paik Paul K.1, Ho Alan L.1, Hantash Feras M.1, Grupe Andrew1, Baxi Shrujal S.1, Callahan Margaret K.1, Snyder Alexandra1, Chi Ping1, Danila Daniel C.1, Gounder Mrinal1, Harding James J.1, Hellmann Matthew D.1, Iyer Gopa1, Janjigian Yelena Y.1, Kaley Thomas1, Levine Douglas A.1, Lowery Maeve1, Omuro Antonio1, Postow Michael A.1, Rathkopf Dana1, Shoushtari Alexander N.1, Shukla Neerav1, Voss Martin H.1, Paraiso Ederlinda1, Zehir Ahmet1, Berger Michael F.1, Taylor Barry S.1, Saltz Leonard B.1, Riely Gregory J.1, Ladanyi Marc1, Hyman David M.1, Baselga José1, Sabbatini Paul1, Solit David B.1, Schultz Nikolaus1
Affiliation:
1. Debyani Chakravarty, Jianjiong Gao, Sarah Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E. Rudolph, Rona Yaeger, Tara Soumerai, Moriah H. Nissan, Matthew T. Chang, Sarat Chandarlapaty, Tiffany A. Traina, Paul K. Paik, Alan L. Ho, Shrujal S. Baxi, Margaret K. Callahan, Alexandra Snyder, Ping Chi, Daniel C. Danila, Mrinal Gounder, James J. Harding, Matthew D. Hellmann, Gopa Iyer, Yelena Y. Janjigian, Thomas Kaley, Douglas A. Levine, Maeve Lowery, Antonio Omuro, Michael A. Postow, Dana...
Abstract
Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base. Methods OncoKB annotates the biologic and oncogenic effects and prognostic and predictive significance of somatic molecular alterations. Potential treatment implications are stratified by the level of evidence that a specific molecular alteration is predictive of drug response on the basis of US Food and Drug Administration labeling, National Comprehensive Cancer Network guidelines, disease-focused expert group recommendations, and scientific literature. Results To date, > 3,000 unique mutations, fusions, and copy number alterations in 418 cancer-associated genes have been annotated. To test the utility of OncoKB, we annotated all genomic events in 5,983 primary tumor samples in 19 cancer types. Forty-one percent of samples harbored at least one potentially actionable alteration, of which 7.5% were predictive of clinical benefit from a standard treatment. OncoKB annotations are available through a public Web resource ( http://oncokb.org ) and are incorporated into the cBioPortal for Cancer Genomics to facilitate the interpretation of genomic alterations by physicians and researchers. Conclusion OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Cited by
1126 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|